GlassScriptPhysician profile
Mark A Zoller
NPI 1558399469
$1,186.92
in general payments reported to CMS, 2019-2025
23 companies · $133 in 2025
The $133 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $542 · 2020: $34.33 · 2021: $92.49 · 2022: $139 · 2023: $228 · 2024: $17.06 · 2025: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $379.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $378.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $338.28 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $121.36 | 2019-2023 | Breztri |
| Pfizer INC. | $71.60 | 2019-2023 | |
| Glaxosmithkline, LLC. | $67.00 | 2019-2023 | Shingrix |
| Exact Sciences Corporation | $61.98 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.43 | 2019-2023 | Jardiance |
| Boston Scientific Corporation | $59.71 | 2022 | |
| Astellas Pharma US INC | $45.85 | 2019-2023 | Myrbetriq |
| Janssen Pharmaceuticals, INC | $41.99 | 2019-2021 | |
| Dexcom, INC. | $38.03 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $36.80 | 2019 | |
| Amgen INC. | $32.40 | 2019 | |
| Medtronic, INC. | $31.36 | 2023-2025 | Closurefast |
| Biohaven Pharmaceutical Holding Company LTD. | $27.19 | 2022 | |
| Lilly USA, LLC | $23.10 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $21.94 | 2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $21.50 | 2022 | |
| Amarin Pharma, INC. | $18.24 | 2019 | |
| Abbott Laboratories | $15.20 | 2021 | |
| Nalpropion Pharmaceuticals LLC | $14.59 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $13.33 | 2023 | Rexulti |
| Abbvie INC. | $12.72 | 2023 | Vraylar |
| Kowa Pharmaceuticals America, INC. | $12.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Zoller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.